Big announcement

1. China Life Insurance plans to issue no more than 35 billion yuan of bonds

$CHINA LIFE (02628.HK)$According to the announcement, the company's board of directors deliberated and passed the “Proposal on Issuance of Capital Supplemental Bonds by the Company”. Depending on market conditions, the company plans to issue capital supplementary bonds totaling no more than RMB 35 billion in domestic capital supplements at one time or in installments. The capital raised by these domestic capital supplementary bonds will be used to supplement the company's subsidiary tier 1 capital and support the continuous and steady development of the business.

2. GDS's net revenue for the third quarter was 2,519 billion yuan, up 6.4% year on year

$GDS-SW (09698.HK)$Net revenue for the third quarter increased 6.4% year over year to 2,519 billion yuan, adjusted EBITDA increased 5.6% year over year to 1,126 billion yuan, and the adjusted EBITDA rate was 44.7%.

3. Baozun e-commerce's net loss in the third quarter narrowed by about 20% year on year

$BAOZUN-W (09991.HK)$Total net revenue for the third quarter was 1,8236 million yuan, up 4.7% year on year; net loss was 126 million yuan, narrowing by about 25% year on year.

4. China Re's original premium income for the first ten months increased 8.6% year on year

$CHINA RE (01508.HK)$It was announced that the total amount of original premium income received in the first ten months through the operating subsidiary China Dadi Property Insurance Co., Ltd. was approximately RMB 42.187 billion, up 8.6% year on year.

Company news

$LINKLOGIS-W (09959.HK)$: Plans to sell 19.608% of Sinopharm Ronghui (Shanghai) commercial factoring shares for 112 million yuan

$CDB LEASING (01606.HK)$: Plans to lease 1.1 billion yuan of offshore wind power equipment assets from Xinneng Haili

$R&F PROPERTIES (02777.HK)$: We are actively communicating and negotiating with relevant creditors

Pharmaceutical Innovation

$REMEGEN (09995.HK)$: Tetaxip is fully approved by China National Drug Administration for the treatment of adult patients with systemic lupus erythematosus

$INNOVENT BIO (01801.HK)$: The State Drug Administration accepts a new drug marketing application for the ROS1 inhibitor telletinib

Funding News

$CHINA EAST AIR (00670.HK)$: To controlling shareholders$China Eastern Airlines Corporation (600115.SH)$The Group carried out 20 billion yuan of perpetual debt financing.

$CHINA LIFE (02628.HK)$: Depending on the circumstances, it is proposed to issue capital supplementary bonds totaling no more than 35 billion yuan.

Repurchase cancellation

$TENCENT (00700.HK)$On November 22, 1.23 million shares were repurchased at a cost of HK$401 million

$AIA (01299.HK)$On November 22, 1,853,600 shares were repurchased at a cost of HK$135 million

$SINOPEC CORP (00386.HK)$On November 22, 7.53 million shares were repurchased at a cost of HK$31.252,500

$KINGSOFT (03888.HK)$On November 22, 688,400 shares were repurchased at a cost of HK$19981 million

$COSCO SHIP HOLD (01919.HK)$Repurchase of 2.7 million shares at a cost of HK$19.5888 million on November 22

$JIUMAOJIU (09922.HK)$On November 22, 1.303 million shares were repurchased at a cost of HK$10.859 million

$ZHIHU-W (02390.HK)$On November 21, 236,400 shares were repurchased at a cost of 4781,000 US dollars

Editor/Corrine